Key Highlights

  • Silence Therapeutics (NASDAQ:SLN) shares soared about 125% on Monday, October 19, 2026 after Merck KGaA agreed to buy the company for USD 20.00 in cash per American depositary share.
  • The offer is a 130% premium to the October 16 close and an 82% premium to the 30-day volume-weighted average price of USD 10.99, giving an equity value of about USD 1.3 billion.
  • Each depositary share represents three ordinary shares, or about USD 6.67 per ordinary share. Silence put the enterprise value at USD 1.1 billion and expects the deal to close in the first quarter of 2027.
  • The gap between a 125% move and a 130% premium means the shares trade slightly below the offer, a merger spread of about 2.2% by simple arithmetic on the published figures.

The Terms of the Merck KGaA Offer

Silence Therapeutics (NASDAQ:SLN) agreed on Monday, October 19, 2026 to be acquired by Merck KGaA, Darmstadt, Germany, for USD 20.00 in cash per American depositary share, according to company filings. Each depositary share represents three ordinary shares, so the price equals about USD 6.67 per ordinary share. The offer is a 130% premium to the closing price on Friday, October 16 and an 82% premium to the 30-day volume-weighted average price of USD 10.99. Silence put the equity value at about USD 1.3 billion and the enterprise value at USD 1.1 billion. The company said the agreement followed a competitive sale process. Closing is expected in the first quarter of 2027, and the shares rose about 125%, as reported by Investing.com.

Why the Shares Trade Just Below the Offer

A 130% premium implies a prior close near USD 8.70, and a 125% gain implies a price near USD 19.57, simple arithmetic on the published figures. The remaining gap of about 2.2% is the merger spread, which pays investors for waiting until closing and for the risk that the deal fails. For Silence Therapeutics (NASDAQ:SLN), a narrow spread signals that the market sees completion as likely. The buyer's interest centres on divesiran, a small interfering RNA medicine, meaning a drug that silences a disease-causing gene, which Merck KGaA is expected to take into Phase 3 trials. The gap between equity and enterprise value suggests net cash of about USD 0.2 billion, an inference from the two published figures.

Risks and What to Watch

The main risk is completion. Silence has filed proxy material with the Securities and Exchange Commission, which points to a shareholder vote, and the deal also needs customary closing conditions to be met. If the transaction failed, the shares could fall back towards their pre-bid level near USD 8.70, well below the 30-day average of USD 10.99. A second risk is timing, because a closing that slips beyond the first quarter of 2027 would lower the annualised return on the spread. For Silence Therapeutics (NASDAQ:SLN), investors should watch the proxy filing and meeting date, any regulatory review and the Fed decision on Wednesday, October 28, since rates set the cost of holding the spread.

Where Things Stand

The answer is that Silence Therapeutics (NASDAQ:SLN) rose about 125% because Merck KGaA offered a fixed USD 20.00 in cash, and the shares now trade close to that price. The spread of about 2.2% reflects the time to a closing expected in the first quarter of 2027 and the risk of failure. The next catalysts are the definitive proxy statement, the shareholder meeting date and regulatory steps. Deal completion is not guaranteed, and this is not investment advice.